ACIP Updates Recommendations on Use of Herpes Zoster Vaccines

On October 20, 2017, Zoster Vaccine Recombinant, a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B) produced by GSK, was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The CDC Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years. The CDC has released a complete discussion on the updated recommendations; see https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm6703a5-H.pdf